Clinical Trials Logo

Clinical Trial Summary

Approximately 600 pediatric patients prescribed Humira Injection in usual practice according to the approved Korean product label will be registered into this observational study. Baseline data will be obtained at enrollment including demographics, underlying diseases and complications especially in regard to purified protein derivative (PPD) skin test, chest X-ray. At routine visits for Humira Injection administration which will occur according to usual medical practice, concomitant medication information and adverse events information will be collected for up to 70 days after the last administration of Humira.


Clinical Trial Description

n/a


Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02141984
Study type Observational
Source AbbVie
Contact
Status Completed
Phase N/A
Start date May 2014
Completion date April 2016

See also
  Status Clinical Trial Phase
Recruiting NCT05411211 - An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Completed NCT04018599 - Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS Phase 1
Completed NCT00144625 - Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) Phase 3
Active, not recruiting NCT05754710 - Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis